View Item 

Show simple item record

Review article: tegaserod — the global experience
dc.contributor.authorChey, William D.en_US
dc.date.accessioned2010-06-01T22:09:15Z
dc.date.available2010-06-01T22:09:15Z
dc.date.issued2004-11en_US
dc.identifier.citationChey, W. D. (2004). "Review article: tegaserod — the global experience." Alimentary Pharmacology & Therapeutics 20(s7): 15-19. <http://hdl.handle.net/2027.42/75175>en_US
dc.identifier.issn0269-2813en_US
dc.identifier.issn1365-2036en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/75175
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=15521850&dopt=citationen_US
dc.description.abstractStudies from the Western hemisphere have established the efficacy and safety of tegaserod in women with irritable bowel syndrome and constipation. This review summarizes the results of recent studies from around the world that confirm the efficacy and safety of tegaserod, and expand our understanding of the role of this drug in the treatment of patients with irritable bowel syndrome.en_US
dc.format.extent81479 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Publishing Ltden_US
dc.rights2004 Blackwell Publishing Ltden_US
dc.titleReview article: tegaserod — the global experienceen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelOtolaryngologyen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.identifier.pmid15521850en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/75175/1/j.1365-2036.2004.02181.x.pdf
dc.identifier.doi10.1111/j.1365-2036.2004.02181.xen_US
dc.identifier.sourceAlimentary Pharmacology & Therapeuticsen_US
dc.identifier.citedreferenceBrandt LJ, Bjorkman D, Fennerty MB, et al. Systematic review on the management of irritable bowel syndrome in North America. Am J Gastroenterol 2002; 97: S7 – 26.en_US
dc.identifier.citedreferenceGershon MD. Serotonin and its implication for the management of irritable bowel syndrome. Rev Gastroenterol Disorders 2003; 3 ( Suppl. 2 ): S25 – 34.en_US
dc.identifier.citedreferenceChey WD. Tegaserod and other serotonergic agents: What is the evidence? Rev Gastroenterol Disorders 2003; 3: S35 – 40.en_US
dc.identifier.citedreferenceCamilleri M. Review article: tegaserod. Aliment Pharmacol Ther 2001; 15: 777 – 89.en_US
dc.identifier.citedreferenceMuller-Lissner S, Fumagalli I, Bardhan KD, et al. Tegaserod, a 5-HT4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating, and constipation. Aliment Pharmacol Ther 2001; 15: 1655 – 66.en_US
dc.identifier.citedreferenceKrumholz S, Tangh J, Schmitt C, Heggland J, Shi Y, Ruegg PC. The 5-HT4 receptor partial agonist tegaserod improves abdominal bloating and altered stool consistency in irritable bowel syndrome. Gut 1999; 45 ( Suppl. V ): A260(Abstract ).en_US
dc.identifier.citedreferenceNovick J, Miner P, Krause R, et al. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2002; 16: 1877 – 88.en_US
dc.identifier.citedreferencevan Zanten SJOV, Talley NJ, Bytzer P, et al. Design of treatment trials for the functional gastrointestinal disorders. In: Drossman DA, ed. Rome II: The Functional Gastrointestinal Disorders, 2nd edn. McLean, VA: Degnon Associates, 2000: Chapter 11.en_US
dc.identifier.citedreferenceTougas G, Snape WJ Jr, Otten MH, et al. Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2002; 16: 1701 – 8.en_US
dc.identifier.citedreferenceLin SR, Zhou LY, Liu XG, et al. Tegaserod provides rapid, effective relief of abdominal pain/discomfort, bloating and constipation in Chinese patients with constipation-predominant irritable bowel syndrome. Gastroenterology 2003; 124 ( 4 Suppl. 1 ): A137(Abstract ).en_US
dc.identifier.citedreferenceKellow J, Lee OY, Chang FY, et al. An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Gut 2003; 52: 671 – 6.en_US
dc.identifier.citedreferenceNyhlin H, Bang C, Eisborg L, et al. A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Scand J Gastroenterol 2004; 39: 119 – 126.en_US
dc.identifier.citedreferenceUscanga-Dominguez L, Cohen Munoz V, on behalf of the Latin America Investigator Group on Tegaserod. Relapse of symptoms following withdrawal of tegaserod treatment in irritable bowel syndrome with constipation. Gastroenterology 2003; 124 ( 4 Suppl. 1 ): A571(Abstract ).en_US
dc.identifier.citedreferenceBardhan KD, Forbes A, Marsden C, et al. Continuous treatment with tegaserod provides improved control of IBS-C symptoms. Gut 2003; 52 ( Suppl. VI ): A93(Abstract ).en_US
dc.identifier.citedreferenceMÜller-Lissner SA, Holtman G, Loeffler H, Ruegg P. Tegaserod is effective in the retreatment of irritable bowel syndrome with constipation. Gastroenterology 2003; 124 ( 4 Suppl. 1 ): A574(Abstract ).en_US
dc.identifier.citedreferenceShah SHA, Jafri SW, Gul M, et al. An open-label study to determine the efficacy and tolerability of tegaserod in the treatment of constipation-dominant irritable bowel syndrome (IBS-C). Gastroenterology 2003; 124: A533(Abstract ).en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1365-2036.2004.02181.x.pdf
Size:
79.56KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.